Absci

Absci EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Absci (ABSI) as of Oct 16, 2026 is -1.94. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -2.88 — a change of -32.69% (higher).

EV/EBITDA

-1.94

YoY

-32.69%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Absci is 2025 -1.94 . EV/EBITDA (Enterprise Value to EBITDA) of Absci was 2024 -2.88 . It decreases by -32.69% higher compared to the previous year.

The Absci EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
-64.31 USD
Jan 1, 2020
-25.65 USD
Jan 1, 2021
-2.05 USD
Jan 1, 2022
-2.49 USD
Jan 1, 2023
-2.90 USD
Jan 1, 2024
-2.88 USD
Jan 1, 2025
-1.94 USD
The Absci EV/EBITDA history
YEAREV/EBITDAYoY
-1.94-32.69%
-2.88-0.68%
-2.90+16.64%
-2.49+21.49%
-2.05-92.02%
-25.65-60.12%
-64.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

EV/EBITDA (Enterprise Value to EBITDA) of Absci is -1.94 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Absci changed from -2.88 to -1.94, representing a -32.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Absci since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Absci with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Absci

All Key Metrics — Absci